ASH 2021 | ANDROMEDA trial: D-VCd versus VCd in the treatment of patients with newly diagnosed AL amyloidosis
In this video, Vaishali Sanchorawala, MD, Boston University School of Medicine, Boston, MA, discusses some results from an updated analysis on the Phase III ANDROMEDA trial (NCT03201965), which aimed to evaluate the use of subcutaneous daratumumab plus bortezomib, cyclophosphamide and dexamethasone (Dara-VCd) versus VCd alone in the treatment of patients with newly diagnosed light chain (AL) amyloidosis. Dr Sanchorawala explains some of the results obtained from this follow-up, including additional safety concerns, complete response (CR) and organ response in both treatment arms. This interview took place at the 63rd ASH Annual Meeting and Exposition congress, Atlanta, GA, 2021.
Disclosures
Takeda: Research Funding; Celgene: Research Funding; Prothena: Membership on an entity’s Board of Directors or advisory committees, Research Funding; Caelum: Membership on an entity’s Board of Directors or advisory committees, Research Funding; Janssen: Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding; Abbvie: Membership on an entity’s Board of Directors or advisory committees; Regeneron: Membership on an entity’s Board of Directors or advisory committees; Proclara: Membership on an entity’s Board of Directors or advisory committees; Pfizer: Honoraria; Karyopharm: Research Funding.
